» Articles » PMID: 18559975

Adenosine Receptors in Regulation of Dendritic Cell Differentiation and Function

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2008 Jun 19
PMID 18559975
Citations 220
Authors
Affiliations
Soon will be listed here.
Abstract

Differentiation of functional dendritic cells (DCs) critically depends on the microenvironment. DCs differentiate in hypoxic tumor sites and inflamed or damaged tissue. Because local concentrations of adenosine reach high physiologically relevant levels in these conditions, we assessed the expression of adenosine receptors and the effect of their activation on differentiation of human monocytes and mouse peritoneal macrophages and hematopoietic progenitor cells (HPCs) into myeloid DCs. Stimulation of adenosine receptors skews DC differentiation toward a distinct cell population characterized by expression of both DC and monocyte/macrophage cell surface markers. Pharmacologic analysis and experiments with cells from A(2B) adenosine receptor knockout mice identified A(2B) receptor as the mediator of adenosine effects on DCs. Unlike normal myeloid DCs, adenosine-differentiated DCs have impaired allostimulatory activity and express high levels of angiogenic, pro-inflammatory, immune suppressor, and tolerogenic factors, including VEGF, IL-8, IL-6, IL-10, COX-2, TGF-beta, and IDO. They promoted tumor growth if injected into tumors implanted in mice. Using adenosine desaminase knockout animals, we showed that DCs with proangiogenic phenotype are highly abundant under conditions associated with elevated levels of extracellular adenosine in vivo. Adenosine signaling through A(2B) receptor is an important factor of aberrant DC differentiation and generation of tolerogenic, angiogenic, and proinflammatory cells.

Citing Articles

CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies.

Gockeln L, Wirsdorfer F, Jendrossek V Front Cell Dev Biol. 2025; 12:1471072.

PMID: 39872847 PMC: 11769960. DOI: 10.3389/fcell.2024.1471072.


Metabolic Signaling in the Tumor Microenvironment.

Clay R, Li K, Jin L Cancers (Basel). 2025; 17(1.

PMID: 39796781 PMC: 11719658. DOI: 10.3390/cancers17010155.


Adenosine signaling in tumor-associated macrophages and targeting adenosine signaling for cancer therapy.

Yang L, Zhang Y, Yang L Cancer Biol Med. 2024; 21(11).

PMID: 39629670 PMC: 11667779. DOI: 10.20892/j.issn.2095-3941.2024.0228.


Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment.

Wang J, He Y, Hu F, Hu C, Sun Y, Yang K Int J Mol Sci. 2024; 25(22).

PMID: 39596288 PMC: 11594648. DOI: 10.3390/ijms252212223.


Impact of the adenosine receptor A2BR expressed on myeloid cells on immune regulation during pregnancy.

Dietz S, Hebel J, Ruhle J, Huff A, Eltzschig H, Lajqi T Eur J Immunol. 2024; 54(12):e2451149.

PMID: 39460389 PMC: 11628929. DOI: 10.1002/eji.202451149.


References
1.
Rivkees S, Reppert S . RFL9 encodes an A2b-adenosine receptor. Mol Endocrinol. 1992; 6(10):1598-604. DOI: 10.1210/mend.6.10.1333049. View

2.
Csoma Z, Huszar E, Vizi E, Vass G, Szabo Z, Herjavecz I . Adenosine level in exhaled breath increases during exercise-induced bronchoconstriction. Eur Respir J. 2005; 25(5):873-8. DOI: 10.1183/09031936.05.00110204. View

3.
Driver A, Kukoly C, Ali S, Mustafa S . Adenosine in bronchoalveolar lavage fluid in asthma. Am Rev Respir Dis. 1993; 148(1):91-7. DOI: 10.1164/ajrccm/148.1.91. View

4.
Frumento G, Piazza T, Di Carlo E, Ferrini S . Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets. 2006; 6(3):233-7. DOI: 10.2174/187153006778250019. View

5.
Feoktistov I, Garland E, GOLDSTEIN A, Zeng D, Belardinelli L, Wells J . Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol. 2001; 62(9):1163-73. DOI: 10.1016/s0006-2952(01)00765-1. View